Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 2/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 2/20 | 1.00 |
| ▸ | HNF4A | P41235 | 1/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | APP | P05067 | 5/20 | 0.70 |
| ▸ | DHODH | Q02127 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938670 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL6266631 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL1048686 | 1.00 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL30075246 | 0.94 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL7711868 | 0.94 | PTPN1 (0.89) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL673426 | 0.94 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL1603423 | 0.94 | PTPN1 (0.89) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL1603420 | 0.94 | PTPN1 (0.89) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL21385358 | 0.94 | PTPN1 (1.00) | PTPN1PTPN2PTPN6HNF4APTGS2 | |
| SCHEMBL23143169 | 0.91 | PTPN1 (0.83) | PTPN1PTPN2PTPN6HNF4APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200138351-A1 | Method for Measuring Fluorescence in Ocular Tissue | COGNOPTIX, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10350309-B2 | Methods of preparing ophthalmic formulations and uses of same | COGNOPTIX, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180126008-A1 | Methods Of Preparing Ophthalmic Formulations And Uses Of Same | COGNOPTIX, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160278677-A1 | Method for Measuring Fluorescence in Ocular Tissue | COGNOPTIX, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9216974-B2 | Phenoxazine derivatives and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9115099-B2 | Phenoxazine derivatives and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150175589-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | UNIV WASHINGTON (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2015072964-A1 | METHOD FOR MEASURING FLUORESCENCE IN OCULAR TISSUE | COGNOPTIX, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015066270-A1 | METHODS OF PREPARING OPHTHALMIC FORMULATIONS AND USES OF SAME | COGNOPTIX, INC. (US) | 2015-05-07 | — | — | WO | disclosed |
| US-20150118163-A1 | Methods of Preparing Ophthalmic Formulations and Uses of Same | COGNOPTIX, INC. | 2015-04-30 | — | — | US | disclosed |
| US-20140221647-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2014-08-07 | — | — | US | disclosed |
| US-8735575-B2 | Phenoxazine derivatives and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20090041666-A1 | Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof | NEUROPTIX CORPORATION | 2009-02-12 | — | — | US | disclosed |
| US-20090041666-A1 | Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof | NEUROPTIX CORPORATION | 2009-02-12 | — | — | US | disclosed |
| WO-2008144065-A1 | OPHTHALMIC FORMULATIONS OF AMYLOID- CONTRAST AGENTS AND METHODS OF USE THEREOF | NEUROPTIX CORPORATION (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2005085189-A2 | ANALOGUES OF CONGO RED AND EVALUATION OF THEIR ANTI-PRION ACTIVITY | MEDICAL RESEARCH COUNCIL (GB) | 2005-09-15 | — | — | WO | disclosed |
| EP-0977815-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND $i(IN VIVO) IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047969-A1 | ALKYL, ALKENYL AND ALKYNYL CHRYSAMINE G DERIVATIVES FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221647-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | PPOX, CYP4Z1, PRDX2 | PTPN1 1577/4885PTPN2 774/4885PTPN6 1782/4885 |
| US-20150175589-A1 | PHENOXAZINE DERIVATIVES AND METHODS OF USE THEREOF | PPOX, CYP4Z1, PRDX2 | PTPN1 1577/4885PTPN2 774/4885PTPN6 1782/4885 |
| US-20090041666-A1 | Ophthalmic formulations of Amyloid-beta contrast agent and methods of use thereof | APP, IAPP, CRYAB | PTPN1 4374/4885PTPN2 4422/4885PTPN6 4470/4885 |
| US-10350309-B2 | Methods of preparing ophthalmic formulations and uses of same | PDE6G, PDE6A, F12 | PTPN1 3100/4885PTPN2 3338/4885PTPN6 3196/4885 |
| US-20200138351-A1 | Method for Measuring Fluorescence in Ocular Tissue | FUCA1, EYA3, ALDH1A2 | PTPN1 4548/4885PTPN2 4465/4885PTPN6 4419/4885 |
| US-20160278677-A1 | Method for Measuring Fluorescence in Ocular Tissue | ALDH1A2, FUCA1, EYA3 | PTPN1 4508/4885PTPN2 4501/4885PTPN6 4345/4885 |
| US-20180126008-A1 | Methods Of Preparing Ophthalmic Formulations And Uses Of Same | PDE6G, PDE6A, F12 | PTPN1 3100/4885PTPN2 3338/4885PTPN6 3196/4885 |
| US-20150118163-A1 | Methods of Preparing Ophthalmic Formulations and Uses of Same | PDE6G, PDE6A, F12 | PTPN1 3100/4885PTPN2 3338/4885PTPN6 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.